期刊
CLINICAL CANCER RESEARCH
卷 17, 期 21, 页码 6822-6830出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-1151
关键词
-
类别
资金
- Antisoma Research Ltd.
- NIH through MD Anderson's Cancer Center [CA016672]
Purpose: AS1402 is a humanized immunoglobulin G1 antibody that targets the aberrantly glycosylated antigen MUC1, which is overexpressed in 90% of breast tumors and contributes to estrogen-mediated growth and survival of breast cancer cells in vitro by modulating estrogen receptor (ER) activity. Aromatase inhibitors have been reported to enhance antibody-dependent cell-mediated cytotoxicity elicited by antibodies in vitro. We compared the outcomes of patients with breast cancer treated with letrozole with or without AS1402. Experimental Design: The study population included 110 patients with locally advanced or metastatic hormone receptor-positive breast cancer randomized to receive 2.5 mg letrozole only once daily or with a weekly 9 mg/kg AS1402 infusion. The primary endpoint was overall response rate. Secondary endpoints included progression-free survival, time to progression, and safety. AS1402 exposure and influence of allotypes of Fc gamma RIIIa, Fc gamma RIIa, and MUC1 were evaluated. Results: The study was stopped early because of a trend toward worse response rates and a higher rate of early disease progression in the AS1402 + letrozole arm. Final analysis revealed no significant difference in efficacy between the study arms. Evaluated gene polymorphisms did not define patient subgroups with improved outcomes. Addition of AS1402 to letrozole was associated with manageable toxicity. Conclusions: Because adding AS1402 to letrozole did not improve outcomes compared with letrozole only, blocking ER maybe a better strategy for harnessing MUC1 modulation of the ER to a clinical advantage. Fc gamma RIIIa, Fc gamma RIIa, and MUC1 allotype did not predict outcome for patients treated with letrozole with or without AS1402. Clin Cancer Res; 17(21); 6822-30. (C)2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据